DEN SELVEJENDE INSTITUTION DANSK BORNEASTMA CENTER

Their core work

COPSAC (Copenhagen Prospective Studies on Asthma in Childhood) is a Danish clinical research center specializing in long-term birth cohort studies to uncover the biological and environmental origins of childhood asthma, allergy, and immune-mediated diseases. Their core asset is a deeply characterized pediatric patient population tracked from birth, enabling them to contribute unique longitudinal data — molecular profiles, immunophenotypes, and environmental exposure records — to large European research consortia. In EU projects, they function as a specialist clinical partner: providing phenotyped cohort data, running immunological assays, and helping map disease subtypes (endotypes) from the ground up. Their work sits at the intersection of clinical medicine, molecular biology, and environmental epidemiology.

What they specialise in

How they've shifted over time

Both H2020 projects started close together (2019–2020), so the "evolution" reflects a parallel deepening rather than a sequential pivot. Their earlier project engagement (BIOMAP) was focused inward on the disease itself — characterizing molecular subtypes and building disease maps using advanced single-cell and immunophenotyping tools. The more recent engagement (HEDIMED) shifted the lens outward — asking what environmental exposures, microbial communities, and dietary patterns actually cause these diseases in the first place. Together, the two projects suggest a coherent scientific strategy: first define the disease precisely at the molecular level, then trace its origins in the exposome.

COPSAC is moving toward integrating environmental exposure science with precision medicine — a combination that positions them well for future consortia focused on disease prevention rather than just treatment.

How they like to work

COPSAC participates exclusively as a consortium partner and has not led any H2020 project, consistent with their role as a specialized clinical data provider rather than a project management hub. They join large, diverse consortia — 55 partners across 18 countries across just two projects — suggesting they are valued as a unique data asset (their birth cohort) that few others can replicate. This means working with them typically involves data access agreements, ethical approvals for cohort data use, and close coordination with their clinical team.

COPSAC has built a surprisingly wide network for a small NGO: 55 unique partners across 18 countries from only two projects, indicating they have been embedded in large pan-European consortia. Their collaborations are predominantly within the EU health research ecosystem, with no obvious geographic concentration beyond Northern Europe.

What sets them apart

COPSAC's key differentiator is their proprietary birth cohort — a longitudinal dataset of children tracked from birth with detailed clinical, molecular, and environmental exposure records, which is rare and expensive to replicate. Few research groups can offer this combination of deep immunophenotyping expertise and a living, consented pediatric cohort spanning allergic and autoimmune diseases simultaneously. For consortia studying the origins of immune-mediated diseases, COPSAC is not a generic clinical site — they are a specific and irreplaceable data source.

Highlights from their portfolio

• BIOMAP
  Their largest project (EUR 544,119) and the one that most directly showcases COPSAC's molecular profiling capabilities, contributing to the first systematic disease map of atopic dermatitis and psoriasis endotypes.
• HEDIMED
  Positions COPSAC within a broader exposome science agenda, expanding their reach beyond skin diseases to type 1 diabetes, celiac disease, and asthma causation through a birth cohort lens.